1
|
Lopez Luis BA, Rodríguez-Díaz R, Angulo-Medina L, Soto-Ramírez LE. The Emergence of Hepatitis C Virus Genotype 4d Among Human Immunodeficiency Virus-Infected Patients in Mexico City: A Molecular Epidemiological Study. Sex Transm Dis 2022; 49:e90-e94. [PMID: 35001015 DOI: 10.1097/olq.0000000000001596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
ABSTRACT The recent detection of hepatitis C virus genotype 4 infection in human immunodeficiency virus-infected patients prompted performing molecular characterization of these isolates. All the Mexican isolates belonged to a subcluster within the 4d group and shared a common ancestor with a French isolate. The estimated timing of introduction in Mexico City was as recent as December 2015.
Collapse
Affiliation(s)
- Bruno Ali Lopez Luis
- From the Laboratory of Molecular Virology, Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan, Mexico City, Mexico
| | | | | | | |
Collapse
|
2
|
Lopez-Osorio MC, Usme-Ciro JA, Martínez JW, Peláez-Carvajal D, Hernández J, Hoyos S, Restrepo JC, Navas MC. Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia. Virus Res 2022; 318:198847. [PMID: 35697300 DOI: 10.1016/j.virusres.2022.198847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 06/06/2022] [Accepted: 06/07/2022] [Indexed: 11/30/2022]
Abstract
Hepatitis C virus (HCV) infection is one of the leading risk factors for end-stage liver disease development worldwide. This RNA virus displays high genetic diversity with 8 genotypes and 96 subgenotypes with heterogeneous geographical distribution around the world. In this study, we carried out an active case finding of individuals with a history of transfusion events before 1996 in three cities in Colombia. Then, the characterization of the HCV genotypes, subgenotypes, and resistance associate substitutions (RAS) was performed in samples positives for antibodies anti-HCV + from this study population. In addition, samples from PWID and patients with end-stage liver disease submitted to liver transplantation were included in the phylogenetic and RAS analysis. The 5'UTR, NS5A, and NS5B regions of the HCV genome were amplified in serum or liver explants samples. After the edition, assembly, and alignment of the sequences, genotyping through phylogenetic analysis was performed using IQTREE V2.0.5 based on the maximum likelihood approach. The identification of RAS was carried out by alignments based on the reference sequence (GenBank NC_004102). Two hundred sixty individuals with blood transfusion events before 1996 were recruited. The seroprevalence of antibodies anti-HCV was 2.69% in this population. The HCV genotypes 1, 2, and 4 and subgenotypes 1a, 1b, 2a, 4a and 4d were characterized in samples of the study populations. Three RAS (Q30R, C316N, and Y93H) were identified in samples obtained from 2 individuals who received blood transfusion before 1996 and without previous antiviral treatment and 6 samples obtained from patients with end-stage liver disease. Among the 20 samples analyzed, the HCV genotype 1, subgenotype 1b, was the most frequent (60%). We report the first characterization of HCV subgenotypes 4a and 4d and the first RAS identification in patients in Colombia.
Collapse
Affiliation(s)
- Maria C Lopez-Osorio
- Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, UdeA. Calle 70 No. 52-21, Medellín, Colombia
| | - José Aldemar Usme-Ciro
- Centro de Investigación en Salud Para el Trópico-CIST, Facultad de Medicina, Universidad Cooperativa de Colombia, Santa Marta 470003, Colombia
| | - José William Martínez
- Facultad de Medicina, Universidad Tecnológica de Pereira, Cra. 27 #10-02, Pereira, Colombia
| | | | - Javier Hernández
- Facultad de Medicina, Universidad del Magdalena, Cra. 32 No. 22 - 08, Santa Marta, Colombia
| | - Sergio Hoyos
- Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, UdeA. Calle 70 No. 52-21, Medellín, Colombia; Hospital Pablo Tobón Uribe, Cl. 78b #69-240 Antioquia, Medellín, Colombia
| | - Juan Carlos Restrepo
- Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, UdeA. Calle 70 No. 52-21, Medellín, Colombia; Hospital Pablo Tobón Uribe, Cl. 78b #69-240 Antioquia, Medellín, Colombia
| | - Maria-Cristina Navas
- Grupo de Gastrohepatología, Facultad de Medicina, Universidad de Antioquia, UdeA. Calle 70 No. 52-21, Medellín, Colombia.
| |
Collapse
|
3
|
Laufer NL, Rockstroh JK. Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. Expert Rev Anti Infect Ther 2013; 12:157-64. [PMID: 24350778 DOI: 10.1586/14787210.2014.868774] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Chronic HCV infection affects 130-170 million individuals worldwide and there are currently 34 million people living with HIV/AIDS. The aim of treatment of HCV is the elimination of the virus (sustained virological response). With development of drugs that specifically target HCV replication, direct-acting agents, sustained virological response rates have dramatically changed for genotype 1 infections. Challenges in the use of direct-acting agents in patients with HIV/HCV co-infection include the potential for drug-drug interactions between HIV and HCV drugs, additional drug toxicities and the need for therapy with IFN-α. Faldaprevir (FDV), previously known as BI 201335, is a second-wave HCV NS3/4A protease inhibitor with highly potent in vitro activity against HCV GT-1a/1b and improved pharmacokinetics suitable for once-daily dosing. FDV is currently in Phase III development. This article will review the pharmacology and pharmacodynamics of FDV, the efficacy and safety of the drug and explore possible future developments in the management of chronic hepatitis C infection, focusing on HIV/HCV co-infected patients.
Collapse
Affiliation(s)
- Natalia Lorna Laufer
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires - CONICET, Buenos Aires, Argentina
| | | |
Collapse
|
4
|
Bolcic F, Laufer N, Trinchero J, Jones LR, Quarleri J. A clustering phenomenon among HCV-1a strains among patients coinfected with HIV from Buenos Aires, Argentina. J Med Virol 2012; 84:570-81. [PMID: 22337295 DOI: 10.1002/jmv.23243] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The human immunodeficiency virus (HIV) and hepatitis C virus (HCV) share the same transmission routes which lead to high coinfection rates. Among HIV-infected individuals such rates reached 21% in Argentina, being HCV-1a the most predominant subtype. In this work, 25 HCV subtype 1a (HCV-1a) strains from Argentinean patients coinfected with HIV were studied based on E2 and NS5A sequences. Phylogenetic analyses indicated that 12 strains were highly related to each other, constituting a highly supported (posterior probability = 0.95) monophyletic group that we called "M." The remaining HCV strains (group dispersed or "D") were interspersed along the phylogenetic trees. When comparing both groups of HCV-1a, 10 amino acid differences were located in functional domains of E2 and NS5A proteins that appeared to affect eventually the peptides binding to MHC-I molecules thus favoring immune escape and contributing to the divergence of HCV genotypes. Bayesian coalescent analyses for HCV-1a cluster M isolates indicated that the time to the most recent common ancestor (tMRCA) overlaps with the age estimated recently for the HIV-BF epidemic in Argentina. Furthermore, the genomic characterization based on pol gene analysis from HIV viremic patients showed that most HIV isolates from patients coinfected with HCV-1a cluster M were BF recombinants with identical recombination patterns. In conclusion, these results suggest the presence of an HCV-1a monophyletic cluster with a potential HIV co-transmission by phylogenetic analyses.
Collapse
Affiliation(s)
- Federico Bolcic
- Microbiology Department, National Reference Center for AIDS Research, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina
| | | | | | | | | |
Collapse
|
5
|
Tang D, Tang J, Su B, Li Q, Chen G. Electrochemical detection of hepatitis C virus with signal amplification using BamHI endonuclease and horseradish peroxidase-encapsulated nanogold hollow spheres. Chem Commun (Camb) 2011; 47:9477-9. [PMID: 21785766 DOI: 10.1039/c1cc13340c] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
A novel electrochemical method to detect hepatitis C virus was developed based on site-specific cleavage of BamHI endonuclease and enzymatic signal amplification with horseradish peroxidase-encapsulated nanogold hollow spheres.
Collapse
Affiliation(s)
- Dianping Tang
- Key Laboratory of Analysis and Detection of Food Safety (Ministry of Education & Fujian Province), Department of Chemistry, Fuzhou University, Fuzhou 350108, PR China.
| | | | | | | | | |
Collapse
|